期刊
FUTURE ONCOLOGY
卷 10, 期 14, 页码 2259-2277出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.139
关键词
F-18-DOPA; Cu-64-DOTATATE; Ga-68-DOTANOC; Ga-68-DOTATATE; Ga-68-DOTATOC; cancer; molecular imaging; neuroendocrine tumors; PET imaging; somatostatin receptor imaging
类别
资金
- Danish National Advanced Technology Foundation
- John and Birthe Meyer Foundation
- Danish Medical Research Council
- Rigshospitalets Research Foundation
- Svend Andersen Foundation
- AP Moller Foundation
- Novo Nordisk Foundation
- Lundbeck Foundation
- Danish Cancer Society
- Novo Nordisk Fonden [NNF13OC0007149] Funding Source: researchfish
- The Danish Cancer Society [R72-A4569] Funding Source: researchfish
Neuroendocrine tumors have shown rising incidence mainly due to higher clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. Ga-68-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison of sensitivity between the most used tracers - Ga-68-DOTA-Tyr3-octreotide, Ga-68-DOTA-Tyr3-octreotate and Ga-68-DOTA-l-Nal3-octreotide - shows little difference and expertise on the specific tracer used, and knowledge regarding physiological uptake might be more important than in vitro-proven differences in affinity. Using isotopes such as F-18 or Cu-64 might improve these PET tracers further.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据